Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. 
Rapid development
Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. 
SARS-COV-2 mouse monoclonal antibodies
Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications.  We report here the development and functional characterization of 29 nM-affinity mouse SARS-CoV-2 mAbs created by an accelerated immunization and hybridoma screening process. 
mAbs
We report here the development and functional characterization of 29 nM-affinity mouse SARS-CoV-2 mAbs created by an accelerated immunization and hybridoma screening process. 
hybridoma screening process